Immatics
gen at tolerability data | Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
74 of 75
Similar slides by Immatics
See diffirences between slides (animation)
Investor Presentation
November 2023
tolerability data cohort gen | Immatics
Investor Presentation
November 2023
gen across all dose levels tolerability data | Immatics
Results
October 2022
tolerability profile all grade adverse events voe | Immatics
Related slides by other companies
Alkermes
Investor Presentation
October 2023
artistry phase potentially registrational study for mucosal melanoma | Alkermes
ATAI
Investor Presentation
March 2023
preliminary data subject to change sedation or dizziness confirms safety profile a both i | ATAI
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase treatment related adverse events in patients all treated patients has not been identified transient asymptomatic grade increase infrequent requiring dose modification discontinued due to dose reduced due to overall avoiding related any alt increased ast increased nausea constipation fatigue peripheral edema grade grade grade any grade resulting in treat resulting in dose reduced dose for source lin grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the city treatment related adverse event at from | Nuvalent
ATAI
Investor Presentation
February 2023
preliminary data subject to change sedation or dizziness confirms safety profile a both i | ATAI
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights